Suppliers / Piramal Healthcare UK

Piramal Healthcare UK

United Kingdom Updated 9 July 2026

The public registers hold a second record for Piramal Healthcare UK. The fuller profile, with 62 active US DMFs and 29 valid CEPs, is at Piramal Pharma. Figures on this page cover only this record.

Piramal Healthcare UK is a finished-dose manufacturer based in United Kingdom. It holds 2 active US drug master files and one valid CEP across a filed portfolio of 2 molecules. Its filings concentrate with MINSA (CR), EDE (AE) and NAFDAC (NG). Its GMP standing is certified by MHRA (UK), NAFDAC (NG) and US FDA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 30 May 2025 as NAI.

2
active US DMFs
1
valid CEPs
8
registered plants 3 with an FDA FEI number
19
filings across 9 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
3 of 3 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 30 May 2025 NAI US FDA
  • 18 March 2022 VAI US FDA
  • 18 June 2021 VAI US FDA
  • 21 September 2018 VAI US FDA
  • 18 May 2018 NAI US FDA
  • 13 January 2017 NAI US FDA
  • 30 January 2015 VAI US FDA
  • 17 October 2014 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Morpeth, United Arab Emirates Not on file
Canada, Canada 3002808377
Morpeth, United Kingdom Not on file
GRANGEMOUTH, United Kingdom Not on file
NORTHUMBERLAND, United Kingdom Not on file
United Kingdom, United Kingdom 3003723155

2 further sites are on record.

What they file, and where

Molecule Regulators Docs
Misoprostol EDQM, US FDA 2
Cloprostenol US FDA 1

Also appears on these molecule pages

Cinacalcet finished dose Norethisterone finished dose Spironolactone finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 5 None
EDE (AE) 5 None
NAFDAC (NG) 3 2
MCAZ (ZW) 1 None
MPA (SE) 1 None
NPRA (MY) 1 None
MHRA (UK) None 12
US FDA None 1
NCELS (KZ) None 1

Questions about Piramal Healthcare UK

Does Piramal Healthcare UK hold a US DMF or a CEP?
Piramal Healthcare UK holds 2 active US drug master files and 1 valid CEP. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Piramal Healthcare UK FDA-registered?
3 sites operated by Piramal Healthcare UK carry an FDA establishment identifier (FEI), which means they are registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Piramal Healthcare UK's last inspection go?
The most recent inspection on record closed on 30 May 2025 as NAI (No Action Indicated: nothing objectionable was found). 8 inspections are on file.
Where does Piramal Healthcare UK manufacture?
8 registered sites are on record, in United Arab Emirates, Canada, United Kingdom and Nigeria (Morpeth, Canada and Grangemouth among others). Every site is listed on this page with the register it came from.
What does Piramal Healthcare UK make?
2 molecules are on record against Piramal Healthcare UK, including Misoprostol and Cloprostenol. Each links through to that molecule's full manufacturer list.
Which regulators recognise Piramal Healthcare UK's GMP?
Current GMP certificates are on record from MHRA (UK), NAFDAC (NG), US FDA and NCELS (KZ). GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Piramal Healthcare UK comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 30 May 2025.

Comparable suppliers

Seacross Pharma (Europe) also in United Kingdom Basildon Chemical also in United Kingdom Norbrook Laboratories also in United Kingdom Croda International also in United Kingdom Fine Organics also in United Kingdom

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates